IDO1 and neoplasm: STING agonists also induced tolerogenic responses that promoted Lewis Lung Carcinoma (LLC) growth in mice by stimulating IDO activity in inflamed lymph nodes draining sites of tumor growth, though cGAS was not essential to induce IDO1 in the LLC model (8).